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Abstract 
Metal stents used in the treatment of percutaneous coronary intervention (PCI) have revolutionized in 
treating atherosclerosis disease. Starting from the emergence of bare metal stent (BMS), this stent 
has been progressively developed into drug-eluting stent (DES) and biodegradable stent. By 
focusing on DES, various drugs have been used to coat metal stent with the aims to overcome in-
stent restenosis and stent thrombosis. Therefore, the utilisation of various drugs and polymers as 
coating materials was reviewed in this study to identify possible alternative to overcome the current 
DES problems. Even though, both complications of BMS are covered successfully by DES, however, 
DES projects long term complications of delayed endotheliasation, delayed wound healing and late 
stent thrombosis. Another alternative of herb coating on DES is considered to be a potential 
approach in improving endotheliasation and retarding smooth muscle cells proliferation to accelerate 
wound healing and to prevent late stent thrombosis.  
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INTRODUCTION 
Cardiovascular disease (CVD) is a disease related to heart and 
blood vessel caused by atherosclerosis that is affecting the entire 
arterial circulation related to pathologic process [1]. Atherosclerosis is 
a build-up of plaque and fatty deposits, cellular debris and cholesterol, 
leads to narrowing of blood vessels [2]. This disease is the leading 
cause of death in the world and surpasses the number of death, caused 
by other diseases such as acquired immunodeficiency syndrome 
(AIDS) and cancer [3]. There are several risk factors that contribute to 
CVD such as obesity, hypertension, diabetes and smoking [1]. In, 
2013, CVD has projected more than 17.3 million deaths per year and 
depicting 31% of all global death [4]. This statistic is presumed to 
increase gradually, up to more than 23.6 million by 2030 [4]. 
In Malaysia, CVD has led to mortality and morbidity of 36% of 
total deaths in 2014 [5]. Therefore, preventions must be taken 
aggressively and more affordable treatments should be offered to aid 
the increasing number of CVD cases. A coronary artery bypass graft 
or a less invasive technique called percutaneous coronary intervention 
(PCI) is a common treatment used to remove the blockage of 
narrowing arteries [2]. Percutaneous coronary intervention, sometimes 
called angioplasty is frequently performed as a treatment for 
atherosclerotic lesions in the coronary artery and usually involves 
balloon angioplasty and stent implantation [6]. 
Stents have been developed rapidly through many years from the 
evolvement of bare metal stent (BMS) to drug-eluting stent (DES) and 
biodegradable stent [6]. Various types of drug are used as coating 
materials to overcome the limitation of BMS where this type of stent 
is known as DES [6]. However, DES also has long term complications 
such as late endotheliasation, delayed wound healing and late stent 
thrombosis [7]. Therefore, the aim of this paper was to provide a 
review on the utilisation of various drugs as coating materials in 
identifying possible alternative to overcome the current complications 
of DES. The review was divided into three sections: Stent; 
Commercial drug coating on DES; Herb coating on DES for 
cardiovascular application. In the first section, elaboration on 
revolution and types of stent were provided while in the second 
section, current commercial drugs which are being used as coating 
materials on DES were discussed to express the main constraint of 
commercial DES. In the third section, several herbs with specific 
therapeutic benefit, that have potential to be used in DES fabrication 
were presented and the final review was focused on ginseng due to its 
dual therapeutic functions.  
Stent 
Stent is a metal wire mesh, used in PCI treatment which requires 
elasticity and strength to support arterial walls in reducing the chance 
of narrowing arteries by keeping the lumen clear from plaque 
development [8–10]. With diameter from 1.5 to 3.0 mm and 15 to 30 
mm long [11], it is also acts as a temporary or permanent vascular 
scaffold, preventing restenosis and incidence of acute vessel blockage 
after dissection as compared with plain old balloon angioplasty 
(POBA) [12]. During PCI treatment, a stent is inserted along with 
balloon catheter to the afflicted coronary artery before it is expanding 
to constrict atherosclerotic plaque [13]. As the balloon catheter is 
inflated and withdrawn from the body, the expanded stent remains in 
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the artery to support the weak arterial wall. In 1964, the first 
angioplasty was introduced by Charles Theodore Dotter and Melvin P. 
Judkins [14] followed by placement of the first coronary angioplasty 
during a coronary artery bypass graft surgery, performed by Gruentzig 
and Myler in May 1977 [6]. Four months later, on 16 September 
1977, Andreas Gruentzig performed the first PCI in an awake patient 
which has been marked as a revolution in interventional cardiology [6, 
15, 16].  
Coronary stent was primarily introduced in the mid-1980s [14], 
acts as a vascular scaffold. It has ousted the POBA as a favoured 
method for PCI treatment, after successful observation on 
angiographic and clinical outcomes [14]. The utilisation of coronary 
stents is revolutionised with major refinements in stent design and 
composition [6]. Implantation of the first coronary BMS was 
performed by Jacques Puel in Toulouse [17] where restenosis rate was 
relatively decreased to 15-30% [3]. Coronary stent implantation was 
then announced as a standard procedure by National Institute for 
Health and Care Excellence (NICE) in the United Kingdom in May 
2000 for treating patients suffering from myocardial infarction [3]. 
Fig. 1 illustrates the evolution of cardiovascular metal stent in treating 
CVD. 
 
Fig. 1 Illustration of evolution of cardiovascular metal stent in treating CVD. 
 
Bare metal stent (BMS) 
Bare metal stent is made of metallic materials such as stainless 
steel, cobalt-chromium, nitinol, etc, established to reduce restenosis 
caused by vascular recoil and to overcome complications after 
dissection [18]. The implantation of BMS is involving several 
procedures. Catheter consists of an inflatable balloon is inserted into 
the artery through a skin cut with a stent, fixed at the end part of the 
balloon [19]. A radial force exerts on the stenotic blood vessel due to 
dilatation of the stent. The stent stays in place and resists contraction 
of the blood vessel caused by permanent deformation [19].  
The restenosis rate was successfully reduced by stent 
implantation, however, an in-stent restenosis (ISR) becomes the 
forthcoming problem with an occurrence of 20-35% [11, 20–21]. In a 
failure case, these neointima tissues that enclosed a stent once the 
stent is implanted into the vessel, proliferate extremely and clog the 
vessel that later trigger hyperplasia [19]. Besides, BMS is also 
regarded as a foreign material that becomes the site of origin for blood 
clot formation and localized inflammation [9]. A profound fibrotic 
response and late lumen damage are another complications of BMS 
where it can reduce arterial diameter by 800 mm due to development 
of 400 mm thick layer of fibrotic tissues within the stent [22]. 
 
Drug-eluting stent (DES) 
Introduction of DES is specifically to overcome the ISR. Drug-
eluting stent is a drug-coated stent which functioned to accommodate 
drugs and to regulate drug release into surrounding tissues [8]. It has 
brought effectively advancement in the management of coronary 
vessel revascularisation. It has also deducted the occurrence of major 
cardiac events from 16.4% (BMS implantation) to 7.8% (DES 
implantation) [23]. Moreover, DES has inhibited the growth of neo-
intimal by releasing an anti-proliferative drug locally, thus 
maintaining vascular patency [24]. Despite of its advantage, DES also 
has limitations in long-term adverse clinical events such as late 
thrombosis, poor vascular endotheliasation, local hypersensitivity and 
delayed wound healing [24]. 
Drug-eluting stent can be divided into three different groups based 
on its structure [25]: 1) Membrane covered stents, where a membrane 
loaded with drug is coated over a stent. The membrane controls the 
release of incorporated drugs into adjacent tissues and minimises loss 
of drug along the lumen when it is only bared to the vessel epithelium. 
However, due to limited anchoring strength at the site of implantation, 
the membrane-covered stent has higher rate of movement in the blood 
vessel. Besides, mechanical properties of the stents are still 
diminished, in longitudinal direction including its flexibility, 
extension capability and collapse pressure.  
2) Drug-reservoirs based stents, where drugs or drug/polymer 
mixture are filled in different shapes of drug reservoirs that are 
formed within the stent struts. The main advantage of this type of 
DES, is the ability to control drug distribution at implantation site by 
changing reservoir design and quantity of drug inside the reservoir. 
However, intricate approaches are needed to form reservoirs within 
the tiny structure of stent struts and to incorporate drug into the 
reservoirs. 3) Layer-coated stents, where stent struts are coated with a 
thin layer of drug integrated carrier. This type of DES has exceptional 
mechanical properties compared to the membrane-covered stents. 
However, the drug is washed away from the action site when this 
monolithic coating layer is exposed to blood stream through the 
lumen.  
All these scenario lead to the development of DES with an 
intention to restrain ISR and neointimal proliferation [26]. Besides, 
requirement for repetition of interventions is reduced and the coronary 
arteries also remain open for lengthy time after the implantation of 
DES [13]. Although DES showed exceptional performance, however, 
late thrombosis and restenosis are still arisen following DES 
implantation [27, 28]. These problems are possibly caused by long 
haul impact of polymer, holding the stent while delivering drug into 
the arterial wall [26]. Another factor is lies on the inability of 
endothelisation around the vessel wall [2]. 
 
Biodegradable stent 
Until the vessel remodels and heals, a biodegradable stent is 
projected to open narrowed blood vessel temporarily before degraded 
progressively [29]. Biodegradable stent is forecasting to restore blood 
flow and to provide mechanical support temporarily to prevent vessel 
recoil [30, 31]. Besides, it needs to possess certain point of fracture 
toughness and sustained deformations in avoiding broken struts or 
fragmentation following implantation [31, 32]. The materials must be 
able to degrade following gradual resorption that match with the 
healing period of blood vessel where inflammatory responses and 
tissue overload should not be provoked by the degradation release 
Figure 1 Click here to download Figure Fig 1.tif 
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[31]. Great biocompatibility, good fatigue and physical resistance to 
aging, ability to withstand high-temperature heat processing, high-
energy laser cutting and critical sterilisation conditions are other 
necessary features required by the materials [31].  
Bioactive stents like DES are notably known for its great 
achievement in curing patients with coronary artery disease. However, 
they still have flaws in long-term repercussion [13]. Therefore, 
clinicians mostly believe that stent is required to reinforce mechanical 
structure of vessel wall transiently during the remedial period as the 
healing of the artery is between 3 and 6 months following stent 
implantation [13]. The possibility of late complications such as 
restenosis and thrombosis due to the placement of permanent device 
can be avoided with utilisation of temporary device that degrades after 
certain period [13]. 
Biodegradable implant offers more than permanent metallic 
implants in terms of physiological reconstruction, reconstitution of 
local vascular compliance, and a brief, limited, longitudinal, and 
radial straightening effects including the probability of growth [33]. 
Materials used in the development of biodegradable stents are 
polymers and metals: either magnesium or iron-based [29, 34]. 
Biodegradable polymers have promising properties to serve as a 
biodegradable implants, however severe inflammation is recorded 
following implantation due to their degradation products. Its slow 
expansion in blood could cause injuries to the blood vessel [35]. As 
for magnesium alloy, it has high mechanical properties compared to 
polymer but it dissolves too fast to match the clinical requirements of 
cardiovascular application [35].  
 
Commercial drug coating on drug-eluting stent 
There are several drugs have been incorporated within polymers 
as a coating material on DES. Two types of commercialised drugs 
commonly used to coat stents are “limus” family and cancer 
chemotherapy drug paclitaxel [22].  
The first generation of DES using sirolimus and paclitaxel hinder 
restenosis by suppressing production of smooth muscle cell, however, 
late stent thrombosis is still occur following the implantation [11]. 
The second generation of DES is the utilisation of sirolimus 
derivatives including everolimus, zotarolimus and biolimus [36–38, 
11]. They revamped clinical results of repeat revascularisation, 
myocardial infarction and stent thrombosis [39, 40]. However, burst 
release of drugs bombarding the occurrence of thrombosis despite of 
their advantages.  
Sirolimus or also known as Rapamycin is a novel 
immunosuppressive agent that can interrupt the pathway of vascular 
endothelium growth factor (VEGF) and limiting tumor production to 
avoid angiogenesis [41]. It has been approved by Food and Drug 
Administration (FDA) as a primary immunosuppressant due to its 
antiproliferative property and its strong anti-rejection effects that 
reduces cardiac allograft vasculopathy and absence of toxicity in the 
kidneys in cardiac transplant patients [42]. A comparison by Park et 
al. [43] showed that cell viability of rabbit iliac artery on tacrolimus-
eluting stent with biodegradable polymer, sirolimus-eluting stent and 
everolimus-eluting stent were reduced in a dose-dependent manner 
where all drugs inhibited smooth muscle cell proliferation. However, 
the growth of endothelial cells was retarded in the treatment with the 
tacrolimus compared to the sirolimus and everolimus [43]. Significant 
different in fibrin score was also reported where the tacrolimus group 
demonstrated better score than the sirolimus and everolimus [43].  
Yazdani et al. [44] evaluated coating integrity as a function of 
time in their in vivo studies by comparing several commercial 
available DES: Xience prime everolimus-eluting stent, Resolute 
zotarolimus-eluting Stent, Taxus paclitaxel-eluting stent and Nobori 
biolimus A9-eluting stent. The everolimus and zotarolimus types of 
DES have less coating deformity than the paclitaxel and biolimus A9 
where coating defect was not observed on most struts [44]. Only a few 
struts of the everolimus type of DES showed minor defects and for the 
zotarolimus type of DES, the struts showed no coating defects at all 
time points except at 180 days [44]. However, webbing and uneven 
coating were noticed on the paclitaxel struts while polymer cracking 
appeared on majority of the biolimus A9 struts [44].  
In a work by Stone et al. [45], a comparison was done on patients 
with ST-segment elevation, suffered from myocardial infarction 
where the disease was treated with paclitaxel-eluting stents and BMS. 
Through international, prospective and controlled trials, the rate of 
angiographic restenosis was significantly decreased [45]. The rate of 
recurrent ischemia required repeat revascularisation method in 
paclitaxel-eluting stent treatment wal also decreased, compared with 
the patients who received BMS within the first year [45]. On the other 
work by Jazi et al. [46], they investigated the effects of implantation 
of BMS and DES on circulating endothelial cells. The studies were 
performed in 22 patients suffered from PCI where the amount of cell 
which acted as cellular markers of endothelial dysfunction following 
PCI was determined, before and after a week of stent implantation 
[46]. The circulating endothelial cells count in the DES group was 
significantly lower compared to the BMS group after one week of 
stent implantation. This finding demonstrated lower endothelial injury 
after the DES implantation.  
Table 1 summarise the previous studies on commercial drug 
coating for DES fabrication which consists of everolimus, 
zotarolimus, paclitaxel, biolimus, sirolimus and tacrolimus. From 
these review, the main constraint of the commercial DES is lying on 
the post-implantation scenario of lack endotheliasation and delayed 
wound healing. Therefore, a review on the utilisation of herb as 
coating materials was done due to its promising values in promoting 
proliferation of endothelial cells and inhibiting differentiation of 
smooth muscle cells to prevent late stent thrombosis. 
 
 
Table 1  Summary of previous studies on commercial drug coating for DES fabrication. 
 
Authors, 
Year 
DES Drug category Review Summary Referenc
e 
Yazdani et 
al., 2016 
Xience prime everolimus-
eluting stent, Resolute 
zotarolimus-eluting stent, 
Taxus paclitaxel-eluting 
stent and Nobori biolimus 
A9-eluting stent 
Everolimus, 
zotarolimus, 
paclitaxel  
and biolimus A9 
Less coating deformity on everolimus and zotarolimus type of 
DES. Minor defects on a few struts of everolimus type of DES and 
no coating defect on zotarolimus type of DES at all time points 
except at 180 days of analysis. Webbing and uneven coating on 
paclitaxel struts and polymer cracking on majority of biolimus A9 
struts. 
 
[44] 
Park et al., 
2015 
Tacrolimus-eluting stent, 
sirolimus-eluting stent and 
everolimus-eluting stent 
Tacrolimus, 
sirolimus  
and everolimus 
Decrement viability of smooth muscle cells in rabbit iliac artery for 
all groups in dose-dependent manner. Growth retardation of 
endothelial cells and higher fibrin score on tacrolimus group 
compared to sirolimus and everolimus groups.  
[43] 
Jazi et al., 
2011 
Sirolimus-eluting stent 
(Cypher) and paclitaxel-
eluting stent (Taxus) 
Sirolimus  
and paclitaxel 
Lower count of endothelial cells on sirolimus and paclitaxel groups 
compared to BMS or non-coating stent after one week of 
implantation 
 
[46] 
Stone et 
al., 2009 
Paclitaxel-eluting stent Paclitaxel Lower rate of angiographic restenosis and lower rate of recurrent 
ischemia on paclitaxel group compared to BMS or non-coating 
stent.  
[45] 
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Herb coating on des for cardiovascular application 
Several herbs (Fig. 2) have been incorporated within polymers for 
the purpose of stent coating. For example, a purified compound of 
Chinese herb medicine, Tripterygium wilfordii or known as Triptolide 
has shown anti-proliferative effect through in vivo and in vitro 
analyses. It has an ability to suppress the proliferation of vascular 
smooth muscle cells, inactivates the pathway of mitogen-activated 
protein kinase (MAPK), modulates the protein cycle of p21cip1 cell 
and reduces the phosphorylation of retinoblasma protein [47]. The 
triptolide-coated stent also displayed attenuation of neointimal 
formation compared to the BMS after one month of implantation [47]. 
In a study by Lee et al. [48], they mixed water extractions derived 
from eight herbal plants  of Pinellia ternate Ten. Ex Breitenb., 
Atractylodes macrocephala Koidz., Gastrodia elata Blume, Citrus 
unshiu Marcow., Poria cocos Wolf, Crataegus pinnatifida Bunge var. 
typica C. K. Schneider, Siegesbeckia pubescens Makino. and Coptidis 
japonica Makino to be coated on stent. They notably found reduction 
in restenosis, retardation of neointimal hyperplasia and inhibition of 
smooth muscle cell growth [48]. However, high dose of these herbal 
plants has slightly increased the toxicity of the samples in their animal 
study [48].  
Karki et al. [49] administrated ethanolic extract of Magnolia 
Cortex (MOE) orally on intimal tissues in rat carotid artery caused by 
balloon endothelial denudation. They expressed that the MOE extract 
which was originated from Magnoliaceae has therapeutic potential in 
the setting of vascular injury as they successfully inhibited the 
migration of smooth muscle cell and suppressed intimal thickening in 
rat carotid artery. In another study, Zulaika et al. [50] worked on the 
development of poly(lactic-co-glycolic acid) (PLGA) and ginsenoside 
coating on stainless steel 316L (SS316L) substrates using a dip 
coating technique as a possible alternative to solve the current 
problems of late restenosis and poor endotheliasation. However, 
further investigation on the ability of the PLGA/ginseng coated stent 
should be carried out as they are presumed can retard the growth of 
smooth muscle cells and promote the proliferation of endothelial cells. 
Table 2 summarise the previous findings on herbs coating on DES. 
 
Table 2 Summary of previous studies on herb coating which possibly be used for DES fabrication. 
 
Authors, 
Year 
Herbs Coating Review Summary Referen
ce 
Tao et al., 
2011 
Triptolide (Tripterygium wilfordii) Suppress proliferation of vascular smooth muscle cells, 
inactivate mitogen-activated protein kinase (MAPK) pathway, 
modulate protein cycle of p21cip1 cell and reduce 
phosphorylation of retinoblasma protein and attenuate 
neointimal formation compared to BMS or non-coated stent 
after one month of implantation. 
[47] 
Lee et al., 
2011 
Water extractions of eight herbal plants (Pinellia 
ternate Ten. Ex Breitenb., Atractylodes 
macrocephala Koidz., Gastrodia elata Blume, 
Citrus unshiu Marcow., Poria cocos Wolf, 
Crataegus pinnatifida Bunge var. typica C. K. 
Schneider, Siegesbeckia pubescens Makino., and 
Coptidis japonica Makino) 
Reduce restenosis, retard neointimal hyperplasia and inhibit 
smooth muscle cell growth. Increase toxicity at high dose of 
water extractions. 
 
[48] 
Karki et al., 
2012 
Ethanolic extract of Magnolia Cortex (MOE) Inhibit migration of smooth muscle cells and suppress intimal 
thickening in rat carotid artery. 
[49] 
 
 
Fig. 2 Potential herbs that can be used for DES coating. 
 
 
Ginseng in cardiovascular application 
Ginseng is one of the herb plants that has been used as an 
alternative remedy since years ago by the people in Eastern Asia 
Countries [51]. People believes that ginseng can cure illness and 
relieves stressful lifestyle [52]. Panax ginseng is belonged to ivy 
family of Araliaceae [53] and it is widely used in Asian countries to 
keep the body homeostasis constant and strengthen the vital energy 
[54]. Panax ginseng can be divided into two types which are red 
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ginseng and white ginseng. Ginsenosides are the main active 
ingredients inside the ginseng, accounted at least 30 different 
ginsenosides, extracted from the roots, stems or leaves of Panax 
ginseng [55]. It has been reported that ginsenosides confer many 
positive impacts to cardiovascular system [56–59]. Based on the 
structure of aglycon with a dammarane skeleton, ginsenosides can be 
divided into three different categories which are protopanaxadiol 
(PPD), protopanaxatriol (PPT) and oleanane saponins [60]. The PPD- 
and PPT- type ginsenosides are further classified into several 
subgroups based on the position and number of sugar moieties 
attached to the aglycon at positions C3 or C6 and C20 [60]. Qin et al. 
[55] reported that the administration of total ginsenosides has 
suppressed monocrotaline (MCT)-induced pulmonary hypertension, 
an established model similar to human pulmonary hypertension. Total 
ginsenosides has significantly decreased full term right ventricular 
systolic pressure, right ventricular hypertrophy index and lung 
weight/body weight in the MCT-induced pulmonary hypertension, 
indicating protective impact on pulmonary hypertension given by the 
total ginsenosides where these results were obtained from the 
assessment of right ventricular systolic pressure and right ventricular 
hyperthropy index.  
Furthermore, Zu et al. [61] verified the protective effect of Rg1 
ginsenoside on intestinal ischemia/reperfusion or hypoxia/ 
reoxygenation by activating the pathway of Wnt/ β-catenin, 
suppressing apoptosis and inhibiting the production of reactive 
oxygen species [61]. The effect of Korean Red Ginseng extract 
(KRGE) also has been tested on apoptosis of human umbilical vein 
endothelial cells (HUVECs) in a serum-deprived apoptosis model 
[62]. The KRGE inhibited serum deprivation-induced apoptotic cell 
death in the HUVECs and displayed protective effect higher than the 
American Ginseng extract (AGE). The KRGE also has an anti-
apoptotic property to prevent endothelial cell death [62]. Interestingly, 
it has an ability to retard tumor cells when tested on anticancer drug 
cisplatin-induced HeLa cells [62]. Ginsenoside Rc is one of the 
compositions in Panax ginseng that exhibit anti-cancer, anti-
inflammatory, anti-obesity and anti-diabetic effects. As shown in a 
flow cytometric analysis, ginsenoside Rc mediates strong anti-
inflammatory activity by blocking Tumor Necrosis Factor-α (TNF-α) 
expression in synovial cells, where TNF-α is a pro-inflammatory 
cytokine that develops rheumatoid arthritis [63]. 
 
Ginseng coating on drug-eluting stent 
Anti-proliferative and anti-thrombotic properties are among 
crucial characteristics required for the development of DES. Both 
properties demonstrate the ability of DES to inhibit the proliferation 
of vascular smooth muscle cells and to promote the proliferation of 
endothelial cells specifically to overcome recent problems of DES 
such as poor endotheliasation, ISR and late thrombosis. In our 
previous research, we have successfully incorporated ginsenosides 
Rg1 and Re with PLGA as a coating material on metallic stent using a 
dip coating technique [49]. However, the theory to retard the 
proliferation of vascular smooth muscle cells and to induce the growth 
of endothelial cells are remain unknown for ginseng coated stent. 
Further analyses are needed to investigate the potential of this stent to 
express their function as DES. Several other techniques also should be 
explored to develop a stable herbal based drug-eluting coating on 
metallic stent that possess optimum characters to function as DES. 
 
CONCLUSION 
 
Stent used in PCI has revolutionized over years in the treatment of 
atherosclerosis, starting from BMS, DES and biodegradable stent. 
Various drugs such as sirolimus, its derivatives and paclitaxel have 
been used as coating materials on DES to overcome restenosis and 
stent thrombosis. However, long term complications of delayed 
endotheliasation, delayed wound healing and late stent thrombosis 
become an obstacle in the implantation of DES. Therefore, providing 
a new strategy is an attempt to combat these problems. The utilisation 
of herbs as coating materials should be considered to be a possible 
way to reduce the current DES complications. 
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